EMPA-KIDNEY
2023
Study of Heart and Kidney Protection with Empagliflozin
In 6,609 patients across a broad spectrum of CKD, empagliflozin reduced kidney-disease progression or cardiovascular death compared with placebo.
Result
Efficacy: CKD progression or cardiovascular deathHR 0.72 (95% CI 0.64-0.82) · P < 0.001
Below 1 favours empagliflozin, above 1 favours placebo.
- Absolute difference
- 3.8 points
- NNT
- 27
Absolute difference and NNT are derived from the event rates.
- Subtopic
- SGLT2 inhibitors
- Design
- Double-blind RCT, stopped early
- Relevance
- Important: one of several pillars.
- Source
- The EMPA-KIDNEY Collaborative Group. N Engl J Med. 2023;388(2):117-127.doi 10.1056/NEJMoa2204233
Discussion & critique
Widest CKD eligibility yet (eGFR down to 20); no significant benefit in the UACR <30 mg/g subgroup.